ATE268605T1 - Pharmazeutische akzeptabel dnase zusammensetzung - Google Patents

Pharmazeutische akzeptabel dnase zusammensetzung

Info

Publication number
ATE268605T1
ATE268605T1 AT95911035T AT95911035T ATE268605T1 AT E268605 T1 ATE268605 T1 AT E268605T1 AT 95911035 T AT95911035 T AT 95911035T AT 95911035 T AT95911035 T AT 95911035T AT E268605 T1 ATE268605 T1 AT E268605T1
Authority
AT
Austria
Prior art keywords
dnase
lung
pharmaceutical acceptable
formulations
individual
Prior art date
Application number
AT95911035T
Other languages
English (en)
Inventor
Hak-Kim Chan
Andrew R Clark
Igor Gonda
Chung C Hsu
Marco Mumenthaler
Steven J Shire
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE268605T1 publication Critical patent/ATE268605T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT95911035T 1994-03-04 1995-02-28 Pharmazeutische akzeptabel dnase zusammensetzung ATE268605T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20602094A 1994-03-04 1994-03-04
US36407494A 1994-12-27 1994-12-27
PCT/US1995/002041 WO1995023613A1 (en) 1994-03-04 1995-02-28 PHARMACEUTICALLY ACCEPTABLE DNase FORMULATION

Publications (1)

Publication Number Publication Date
ATE268605T1 true ATE268605T1 (de) 2004-06-15

Family

ID=26900974

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95911035T ATE268605T1 (de) 1994-03-04 1995-02-28 Pharmazeutische akzeptabel dnase zusammensetzung

Country Status (6)

Country Link
EP (1) EP0748225B1 (de)
JP (1) JP2986215B2 (de)
AT (1) ATE268605T1 (de)
CA (1) CA2184582C (de)
DE (1) DE69533128T2 (de)
WO (1) WO1995023613A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
DE69332105T2 (de) 1992-09-29 2003-03-06 Inhale Therapeutic Systems, San Carlos Pulmonale abgabe von aktiven fragmenten des parathormons
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
EP0748213B1 (de) 1994-03-07 2004-04-14 Nektar Therapeutics Verfahren und mittel zur verabreichung von insulin über die lunge
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
JP2001507701A (ja) * 1996-12-31 2001-06-12 インヘイル・セラピューティック・システムズ・インコーポレーテッド 親水性賦形剤を有する疎水性薬剤の溶液を噴霧乾燥するための方法及びその方法によって作製された組成物
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6451349B1 (en) 1998-08-19 2002-09-17 Quadrant Healthcare (Uk) Limited Spray-drying process for the preparation of microparticles
GB9814172D0 (en) * 1998-06-30 1998-08-26 Andaris Ltd Formulation for inhalation
US6926911B1 (en) * 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
WO2001085136A2 (en) 2000-05-10 2001-11-15 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
EP1992335A1 (de) 2001-11-01 2008-11-19 Nektar Therapeutics Sprühtrocknungsverfahren und Zusammensetzungen dafür
JP2005514393A (ja) 2001-12-19 2005-05-19 ネクター セラピューティクス アミノグリコシドの肺への供給
AU2003245794A1 (en) * 2002-02-18 2003-09-04 University Of Southampton Glycosaminoglycan-dnase combination therapy
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
AU2003297320B8 (en) * 2002-12-17 2008-02-21 Medimmune, Llc High pressure spray-dry of bioactive materials
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
RU2269356C2 (ru) * 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения онкологических заболеваний
US8916151B2 (en) 2005-04-25 2014-12-23 Cls Therapeutics Limited Method for treating a reduction of fertility
JP5372769B2 (ja) 2006-11-28 2013-12-18 シーエルエス セラピューティック リミティド 組織の細胞外間隙においてデオキシリボ核酸の量が増量することに関連するヒトの病気の治療方法及び該方法を実施するための医薬製剤
WO2009120619A2 (en) * 2008-03-24 2009-10-01 Novartis Ag Nuclease compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions
EP2389162A1 (de) 2009-01-26 2011-11-30 Teva Pharmaceutical Industries Ltd Verfahren zur beschichtung eines trägers mit mikroteilchen
WO2011038901A1 (en) * 2009-09-29 2011-04-07 Activaero Gmbh Improved method for treatment of patients with cystic fibrosis
CN103920144B (zh) * 2013-01-15 2016-09-14 吴庄民 重组人的脱氧核糖核酸酶i的新应用
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
US11701410B2 (en) 2015-05-22 2023-07-18 Cls Therapeutics Limited Extracellular DNA as a therapeutic target in neurodegeneration
AU2019209770B2 (en) 2018-01-16 2025-07-31 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4233405A (en) 1979-10-10 1980-11-11 Rohm And Haas Company Process for spray drying enzymes
DE68929551T2 (de) * 1988-12-23 2008-03-06 Genentech, Inc., South San Francisco Menschliche DNase
GB9010742D0 (en) * 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
JPH04271785A (ja) * 1991-02-28 1992-09-28 Kao Corp 酵素固形製剤及びその製造方法
US5279823A (en) 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE

Also Published As

Publication number Publication date
DE69533128D1 (de) 2004-07-15
JP2986215B2 (ja) 1999-12-06
WO1995023613A1 (en) 1995-09-08
CA2184582C (en) 2001-12-25
EP0748225B1 (de) 2004-06-09
JPH09509927A (ja) 1997-10-07
EP0748225A1 (de) 1996-12-18
CA2184582A1 (en) 1995-09-08
DE69533128T2 (de) 2005-06-09

Similar Documents

Publication Publication Date Title
DE69533128D1 (de) Pharmazeutische akzeptabel dnase zusammensetzung
HUT60630A (en) Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature
YU49698A (sh) Smeše koje sadrže tetrahidrolipstatin
MY117892A (en) Therapeutic compounds
IT1255390B (it) Prodotti farmaceutici per curare malattie tumorali e procedimento per la loro preparazione
BG102689A (bg) Фармацевтичен аерозолен състав за използване при лечение на респираторни смущения
NO156275C (no) Fremgangsmaate for fremstilling av kapsler inneholdende et toert, pulverformet allergenpreparat.
NO931267L (no) Fremgangsmaate for behandling eller forebyggelse av type 1diabetes ved oral administrering av insulin
DE69104830D1 (de) Darreichnungsform zur verabreichnung eines antiparkinsonsmittel.
CA2293470A1 (en) Benzimidazole derivatives
BR9610059A (pt) Método para detectar doença pulmomar
YU47543B (sh) Postupak za dobijanje farmaceutskog preparata za stimulaciju granulocita
SE9704833D0 (sv) New formulation
DK0630230T3 (da) Farmaceutiske inhaleringspræparater
NO20001087D0 (no) Medikament for forlengelse av muskelfunksjon eller behandling av muskelforstyrrelser eller -sykdommer
FR2724384B1 (fr) Nouveaux derives de la 3,4-dihydro beta-carboline agonistes de la melatonine, leur procede de preparation et leur utilisation a titre de medicament
PT98371A (pt) Processo para a preparacao de derivados 6-alcoxi de arabinofuranosil-guanina e de composicoes farmaceuticas que os contem
HUP9700806A2 (hu) Tianeptin-nátriumsó nyújtott felszabadulását biztosító, szájon át beadható mátrix tabletta és eljárás előállítására
MX9805441A (es) Compuestos terapeuticos.
NZ505538A (en) A vaccine comprising immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide (PIM); and the use of PIM for inducing an immune response in a patient effective in the prevention or treatment of Th2-mediated diseases or disorders such as asthma
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
TNSN92115A1 (fr) Succedanes de benzimidazoles, processus de leur preparation ainsi que de leur utilisation
HUP9900945A2 (hu) Nukleozidanalógok herpes simplex vírus fertőzések kombinációs terápiájában
ATE141510T1 (de) Arzneimittel enthaltend cd14
ATE12649T1 (de) Optisch aktives dipeptide, seine pharmazeutisch vertraeglichen salze, verfahren zur herstellung und diese enthaltende pharmazeutische praeparate.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0748225

Country of ref document: EP